3.4.11.3: cystinyl aminopeptidase
This is an abbreviated version!
For detailed information about cystinyl aminopeptidase, go to the full flat file.
Word Map on EC 3.4.11.3
-
3.4.11.3
-
envelope
-
pregnancy
-
cd4
-
epitope
-
lymphocyte
-
angiotensin
-
vaccinia
-
viruses
-
women
-
aminopeptidases
-
hiv-1-infected
-
humoral
-
t-cells
-
virion
-
simian
-
macaque
-
hiv-specific
-
immunodominant
-
nef
-
seroconversion
-
chimpanzee
-
anti-hiv-1
-
seronegative
-
insipidus
-
syncytium
-
prime-boost
-
furin
-
vaccinees
-
seropositive
-
vaccine-induced
-
glut4-containing
-
hiv-seronegative
-
desmopressin
-
shiv
-
ddavp
-
hiv-1iiib
-
anti-cd4
-
intrarectal
-
sivmac239
-
medicine
-
alum
-
seroconverted
-
1-infected
-
non-neutralizing
-
diagnostics
-
oligosaccharyltransferase
-
virus-neutralizing
-
cross-neutralizing
-
pharmacology
-
coreceptors
-
cross-presentation
-
nephrogenic
-
radioimmunoprecipitation
- 3.4.11.3
- envelope
- pregnancy
- cd4
- epitope
- lymphocyte
- angiotensin
- vaccinia
- viruses
- women
- aminopeptidases
-
hiv-1-infected
-
humoral
- t-cells
- virion
-
simian
- macaque
-
hiv-specific
-
immunodominant
- nef
- seroconversion
- chimpanzee
-
anti-hiv-1
-
seronegative
- insipidus
-
syncytium
-
prime-boost
- furin
-
vaccinees
-
seropositive
-
vaccine-induced
-
glut4-containing
-
hiv-seronegative
- desmopressin
- shiv
-
ddavp
-
hiv-1iiib
-
anti-cd4
-
intrarectal
-
sivmac239
- medicine
-
alum
-
seroconverted
-
1-infected
-
non-neutralizing
- diagnostics
-
oligosaccharyltransferase
-
virus-neutralizing
-
cross-neutralizing
- pharmacology
-
coreceptors
-
cross-presentation
-
nephrogenic
-
radioimmunoprecipitation
Reaction
Release of an N-terminal amino acid, Cys-/-Xaa-, in which the half-cystine residue is involved in a disulfide loop, notably in oxytocin or vasopressin. Hydrolysis rates on a range of aminoacyl arylamides exceed that for the cystinyl derivative, however =
Synonyms
alpha-Aminoacyl-peptide hydrolase, aminopeptidase, cystyl, AT4 receptor, CAP, CAP-I, CAP-II, CysAP, cysteine aminopeptidase, cystine aminopeptidase, Cystinyl aminopeptidase, cystinylaminopeptidase, cystyl aminopeptidase, cystyl-aminopeptidase, GP160, insulin regulated aminopeptidase, insulin-regulated aminopeptidase, insulin-regulated aminopeptidase IRAP, Insulin-regulated membrane aminopeptidase, Insulin-responsive aminopeptidase, IRAP, IRAP/P-LAP, L-cystine aminopeptidase, LCAP, LeuAP, leucine aminopeptidase/oxytocinase, leucyl-aminopeptidase, leucyl-cystinyl aminopeptidase, LNPEP, M1 aminopeptidase, OTase, oxytocin peptidase, oxytocinase, oxytocinase/insulin-regulated aminopeptidase, oxytocinase/vasopressinase-like leucyl-cystinyl aminopeptidase LNPEP, P-LAP, P-LAP/IRAP, P-LAP/OTase, placental leucil aminopeptidase, Placental leucine aminopeptidase, placental leucine aminopeptidase/oxytocinase, placental leucine aminopeptidase/oxytocinase/insulin-regulated membrane aminopeptidase, vasopressinase, vasopresssinase, Vesicle protein of 165 kDa, Vp165, yscXVI
ECTree
3.4.11.3 cystinyl aminopeptidaseAdvanced search results
results (
results (Application
Application on EC 3.4.11.3 - cystinyl aminopeptidase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
APPLICATION 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
diagnostics
the increase in serum IRAP activity can be an indicator of a misregulation of vasopressin (AVP) function
medicine
pharmacology
medicine
-
development of stable second generation inhibitors of IRAP based on the AT4 ligands angiotensin IV or LVV-H7 may provide the opportunity for the development of therapeutics for memory loss in patients Altheimer's disease
medicine
-
P-LAP is an independent prognosticator of clinical outcome in patients with endometrial carcinoma. Assessment of the P-LAP status provides clinically useful prognostic information in patients with endometrial carcinoma
medicine
-
P-LAP is available for evaluation of avarian epithelial malignancy and also as target for molecular therapy
medicine
-
the enzyme is suggested to be involved in reducing chemosensitivity and may be a therapeutic target in endometrial carcinoma
medicine
-
activities of soluble cystyl aminopeptidase do not differ between diabetic and control rats in both hippocampus and hypothalamus. Membrane-bound cystyl aminopeptidase is about 2.5foldincreased in the hypothalamus and 5fold increased in the hippocampus
medicine
-
blocking of alpha-1adrenoceptor by doxazosin increases enzyme activity in male, but not in female thalamus. Increased capacity of males to degrade vasopressin and to regulate cardiovascular homeostasis
medicine
-
enzyme isoform IRAP is involved in increasing malignant potential of endometrial cancer mediated by insulin. Endometrial adenocarcinoma A-MEC cells expressing the enzyme exhibit a significant growth-stimulatory effect compared with control. They have a remarkably high level of p85PI3K protein and show a higher degree of AKT phosphorylation by insulin stimulation
medicine
-
marked decrease of membrane-bound cystinyl aminopeptidase activity in clear cell renal carcinoma cell, papillary renal carcinoma cell, and chromophobe renal carcinoma cell compared to surrounding non-tumor tissue. Minor and non-significant changes of enzyme activity in soluble fractions of carcinoma cells
medicine
-
Otsuka Long Evans Tokushima Fatty rats, model of type II Diabetes mellitus, show significantly lower cell surface IRAP equilibrium activity than control. Time to reach equilibrium is significantly longer and adipocytes isolated from the model rats demonstrate both a delay and a reduction in 3-O-methyl-D-glucose uptake
medicine
-
plasma activities of cystinyl-, aspartyl-, and glutamyl-aminopeptidase are decreased by 39.4%, 24.9%, and 33.3%, respectively, in patients with Parkinson's disease
medicine
-
excessive activity of vasopressinase is probably responsible for gestational diabetes insipidus
pharmacology
enzyme IRAP is a therapeutic target for the treatment of limbic seizures
pharmacology
-
enzyme IRAP is a therapeutic target for the treatment of limbic seizures
-
